Getting an accurate diagnosis in patients with suspected mesothelioma can be challenging^1-3. Many primary lung cancers eventually involve the lung pleura, and several other cancers can metastasize to the lung. Knowing the risk factors, eg, exposure to mesothelioma related-substances, should trigger the need for additional diagnostic information.

In the absence of specific clinical biomarkers, mesothelioma can be difficult to differentiate from other malignancies². Lung cancers can vary substantially in appearance and differentiation from microscopic field to field³. The diagnostic value of antibodies and immunohistochemical panels is still under debate². And pathological diagnosis often suffers from significant interobserver variability³.

A single, conclusive test for malignant pleural mesothelioma is finally available. miRview® meso is designed to differentiate mesothelioma from adenocarcinoma and other carcinomas of the lung and pleura and can also help physicians rule out mesothelioma in patients who have been exposed to mesothelioma-related substances. It delivers a differential diagnosis of mesothelioma with:

• Accuracy
• Speed
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
2. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397-401.
3. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.